Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
NCT04451837Phase 2Active, not recruiting
- Sponsor
- Region Skåne
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide, dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Region Skåne. Started Sep 2020; status: active, not recruiting.
02
Drugs
semaglutidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04451837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04451837.